method
analysi
studi
design
multicentr
randomis
doubleblind
doublesimul
oseltamivirand
placebocontrol
paralleldesign
clinic
trial
elig
increas
evid
clinic
use
cld
granul
treat
season
influenza
take
robust
patient
followup
studi
flowchart
shown
fig
followup
period
specif
item
collect
see
onlin
supplementari
appendix
remedi
period
particip
requir
regist
daili
record
symptom
ensur
safeti
patient
blind
studi
design
data
qualiti
adher
studi
protocol
personnel
particip
directli
studi
adequ
train
follow
guidelin
good
clinic
practic
gcp
tabl
particip
meet
reject
criteria
remov
data
includ
final
statist
analysi
howev
termin
standard
relat
enrol
patient
may
termin
remedi
period
data
patient
includ
final
statist
analysi
reject
criteria
termin
standard
detail
tabl
tabl
base
detail
symptom
shown
tabl
patient
divid
two
type
accord
two
tcm
practition
suffici
time
opinion
fulli
consid
trial
entri
ask
question
investig
written
inform
consent
sign
patient
will
particip
clinic
trial
research
doctor
obtain
written
consent
patient
will
particip
trial
addit
biolog
sampl
obtain
store
use
futur
studi
materi
consent
obtain
specif
address
collect
serum
plasma
specimen
patient
group
administ
four
bag
cld
granul
bag
half
hour
meal
three
time
daili
day
taken
analog
oseltamivir
capsul
twice
daili
day
test
drug
within
trial
period
pack
panlongyunhai
pharmaceut
compani
drug
count
sort
third
parti
chines
evidencedbas
medicin
center
west
china
hospit
sichuan
univers
china
drug
within
expir
date
treatment
may
taken
particip
follow
symptom
axillari
temperatur
last
h
reduc
physic
cool
bodi
temperatur
headach
myalgia
score
point
symptomat
treatment
measur
follow
fever
acetaminophen
b
sever
cough
white
phlegm
bisolvon
c
mild
asthmat
symptom
longact
theophyllin
drug
may
use
detail
inform
drug
use
regist
crf
investig
instruct
particip
record
actual
dose
patient
diari
base
diari
investig
evalu
subject
adher
intervent
follow
four
level
record
result
case
report
form
followup
take
prescrib
medic
basic
prescrib
medic
dose
data
entri
manag
respons
assign
data
manag
establish
databas
verif
procedur
two
specialis
train
keyboard
oper
input
confirm
data
check
crf
identifi
entri
error
correct
input
data
exactli
crf
queri
crf
commun
research
data
queri
form
data
queri
form
must
process
sign
date
time
research
resolv
data
question
must
return
data
manag
revis
verifi
data
accord
feedback
correspondingli
updat
databas
necessari
data
question
form
queri
databas
lock
confirm
accuraci
establish
databas
blind
review
lock
data
chang
data
revis
need
lock
offici
statement
jointli
sign
sponsor
main
research
experiment
project
manag
statistician
data
manag
must
provid
addit
revis
perform
statist
analysi
data
review
case
assess
confirm
intenttotreat
popul
ittp
modifi
intenttotreat
popul
mittp
perprotocol
popul
ppp
safeti
analysi
popul
sap
decis
approv
data
manag
studi
promot
research
end
unblind
lock
databas
primari
outcom
primari
outcom
time
allevi
influenzalik
symptom
fever
stuffi
nose
run
nose
sore
throat
cough
myalgia
fatigu
headach
chill
sweat
measur
hour
allevi
mean
influenzalik
symptom
score
mild
state
stabl
secondari
outcom
secondari
endpoint
consist
seven
aspect
ii
area
curv
auc
analysi
nine
influenzalik
symptom
score
provid
indic
diseas
sever
auc
calcul
product
daili
symptom
score
multipli
durat
ill
iii
treatment
efficaci
differ
tcm
syndrom
assess
tcm
syndrom
score
indic
vital
sign
cardiopulmonari
sign
electrocardiographi
clinic
laboratori
test
biochemistri
haematolog
urin
examin
compar
treatment
assess
safeti
addit
research
interview
keep
touch
particip
monitor
safeti
advers
event
vital
sign
symptom
diseas
laboratori
paramet
patient
occur
enter
clinic
trial
record
occurr
advers
event
necessarili
relat
studi
drug
advers
event
divid
three
level
mild
committe
causeandeffect
relationship
advers
event
studi
drug
determin
classif
shown
tabl
patient
seriou
advers
event
necessari
know
specif
situat
permiss
obtain
consent
main
investig
emerg
letter
read
case
treat
shed
organ
influenzalik
ill
ili
use
basi
influenza
surveil
patient
present
acut
cough
fever
clinician
must
highli
vigil
test
infect
caus
influenza
viru
gener
rate
ili
case
lead
clinic
diagnosi
influenza
infect
approxim
higher
clinic
diagnos
exampl
acut
infect
upper
respiratori
tract
select
adult
ili
patient
inclus
studi
furthermor
trial
confirmatori
studi
treatment
influenza
cld
granul
patient
randomli
assign
three
group
posit
group
test
group
placebo
group
trial
number
sampl
case
estim
base
test
hypothesi
test
group
superior
placebo
group
test
group
inferior
posit
control
group
main
index
treatment
effect
period
time
subsid
symptom
hour
report
averag
period
time
remiss
symptom
placebo
group
day
hour
trial
requir
averag
time
symptomat
remiss
test
group
least
hour
shorter
placebo
group
mean
permiss
error
superior
trial
hour
order
consid
clinic
signific
mean
time
symptomat
remiss
posit
group
must
less
hour
compar
placebo
group
mean
permiss
error
superior
trial
within
hour
calcul
data
follow
local
advertis
particip
receiv
financi
compens
finish
entir
treatment
patient
drop
payment
prorat
length
time
stay
studi
payment
made
studi
would
complet
statist
analysi
clinic
data
manag
analys
third
parti
chines
evidencedbas
ii
modifi
intenttotreat
popul
mittp
randomis
studi
drug
use
least
intervent
effect
outcom
record
least
iii
perprotocol
popul
ppp
ppp
case
includ
case
meet
inclus
criteria
full
accord
iv
safeti
analysi
popul
sap
randomis
studi
drug
taken
least
intervent
effect
safeti
evalu
data
record
least
experi
baselin
data
efficaci
analysi
analys
mittp
simultan
primari
efficaci
endpoint
ppp
analysi
conclus
mainli
base
mitt
analysi
result
mittp
analysi
ppp
analysi
consist
credibl
conclus
increas
miss
data
last
observ
carryforward
locf
method
use
extrapol
data
sap
use
examin
laboratori
data
advers
event
advers
reaction
rate
advers
reaction
employ
sap
denomin
statist
softwar
use
ii
statist
infer
use
twosid
test
statist
signific
mean
p
confid
interv
paramet
estim
use
confid
interv
iii
efficaci
analys
locf
use
compens
case
inform
patient
record
treatment
last
observ
data
transfer
final
test
result
safeti
analysi
estim
miss
data
iv
comparison
dropout
rate
dropout
rate
caus
advers
event
undertaken
use
pearson
test
v
measur
data
given
mean
standard
deviat
confid
interv
necessari
minimum
maximum
median
provid
pair
measur
data
also
use
demonstr
differ
mean
standard
deviat
nonparametr
method
median
mean
rank
provid
count
data
frequenc
distribut
correspond
percentag
level
data
given
frequenc
distribut
correspond
percentag
well
median
mean
rank
qualit
inform
show
posit
rate
number
posit
case
denomin
vi
baselin
data
analys
two
set
involv
demograph
indic
gener
situat
primari
secondari
indic
intervent
measur
data
analys
use
test
test
varianc
homogen
count
data
analys
use
pearson
test
rate
data
analys
use
two
sampl
wilcoxon
rank
sum
test
vii
efficaci
analys
quantit
variabl
comparison
group
use
repetit
measur
analysi
varianc
covari
analysi
qualit
variabl
comparison
group
use
pearson
test
centr
effect
analysi
use
cmh
test
rate
variabl
group
comparison
test
kruskalw
test
central
effect
analysi
test
cmh
test
grade
logist
regress
viii
centr
effect
analysi
clm
cmh
method
use
quantit
qualit
indic
respect
logist
regress
model
perform
evalu
correct
rate
variabl
ix
subgroup
analysi
difficult
prevent
specif
circumst
data
affect
outcom
x
safeti
analysi
pearson
test
use
compar
preval
advers
event
two
set
advers
event
occur
trial
list
describ
descript
laboratori
test
result
normalabnorm
chang
experi
well
relationship
abnorm
chang
test
drug
record
chang
also
list
describ
advers
event
refer
advers
medic
event
occur
time
patient
sign
inform
consent
form
select
trial
time
last
followup
whether
causal
relationship
incid
advers
event
studi
drug
advers
event
type
degre
time
treatment
measur
treatment
process
record
crf
relationship
advers
event
studi
drug
base
comprehens
consider
comorbid
medic
physician
decid
whether
suspend
observ
patient
followup
survey
carri
case
patient
withdrawn
advers
event
result
record
detail
appropri
time
incid
advers
event
treatment
review
comprehens
analys
determin
whether
advers
event
relat
studi
drug
advers
event
lead
discontinu
treatment
seriou
advers
event
summaris
addit
confid
interv
advers
event
use
fisher
exact
test
calcul
fisher
exact
test
use
compar
preval
advers
event
cld
granul
oseltamivir
placebo
trial
publicis
region
nation
confer
final
result
present
scientif
meet
publish
peerreview
journal
authorship
accord
journal
guidelin
addit
lay
summari
studi
result
circul
potenti
interest
parti
sinc
lack
clinic
trial
tradit
chines
herbal
medicin
tchm
effect
also
safeti
tchm
investig
studi
evalu
safeti
chang
liver
kidney
function
treatment
monitor
studi
divid
patient
cold
heat
tcm
syndrom
studi
whether
f
r
p
e
e
r
r
e
v
e
w
particip
termin
meet
one
termin
standard
patient
ill
becom
sever
sever
meet
one
follow
criteria
persist
high
fever
day
ii
sever
cough
purul
sputum
bloodi
sputum
plausibl
caus
owe
diseas
explan
use
experiment
drug
reason
relationship
time
similar
pharmacolog
effect
drug
experiment
drug
well
known
difficult
identifi
caus
owe
diseas
explan
use
experiment
drug
reason
relationship
time
advers
event
may
caus
diseas
explan
connect
time
test
drug
easi
explain
diseas
main
symptom
diseas
connect
time
test
drug
complet
checklist
enter
page
number
manuscript
reader
find
item
list
articl
may
current
address
item
checklist
pleas
modifi
text
includ
miss
inform
certain
item
appli
pleas
write
na
provid
short
explan
upload
complet
checklist
extra
file
submit
journal
method
section
say
use
spirit
report
guidelin
cite
studi
design
multicentr
randomis
doubleblind
doublesimul
oseltamivirand
placebocontrol
paralleldesign
clinic
trial
elig
subject
n
alloc
satisfi
criteria
western
medicin
subject
randomis
receiv
cld
granul
oseltamivir
placebo
day
treatment
followup
western
medic
method
evalu
efficaci
chines
herbal
medicin
suit
lack
maturetradit
chines
medicin
evalu
system
develop
cld
target
drug
less
side
effect
wide
use
prevent
treatment
influenza
indepth
studi
need
conduct
studi
multicentr
randomis
doubleblind
doublesimul
approach
use
hope
clinic
efficaci
cld
treatment
influenza
fulli
verifi
highest
level
clinic
trial
object
empir
evid
treatment
cld
posit
outcom
influenza
viru
infect
yet
evidencebas
clinic
trial
conduct
seek
gain
indepth
understand
efficaci
safeti
cld
use
influenza
infect
evidencebas
medicin
clinic
studi
addit
investig
whether
cld
granul
differ
therapeut
effect
differ
tcm
syndrom
differenti
compar
symptom
treatment
followup
period
specif
item
collect
see
onlin
supplementari
appendix
remedi
period
particip
requir
regist
daili
record
symptom
refer
inclus
exclus
criteria
shown
patient
enrol
meet
inclus
criteria
enrol
one
exclus
criteria
patient
remov
trial
meet
one
reject
criteria
termin
standard
enrol
particip
requir
provid
written
inform
consent
cooper
doctor
treatment
cooper
followup
provid
inform
beyond
remit
ethic
approv
patient
compli
remov
studi
period
pharyngealthroat
swab
blood
sampl
collect
particip
particip
also
distinguish
accord
tcm
syndrom
differenti
criteria
describ
studi
design
enrol
patient
six
unit
iv
sign
written
inform
consent
exclus
criteria
detail
tabl
particip
meet
reject
criteria
remov
data
includ
final
statist
analysi
howev
termin
standard
relat
enrol
patient
may
termin
remedi
period
data
patient
includ
final
statist
analysi
reject
criteria
termin
standard
detail
tabl
tabl
base
detail
symptom
shown
tabl
patient
divid
two
type
accord
doctor
confirm
patient
satisfi
particip
criteria
consent
given
subsequ
discuss
patient
medic
offic
trial
team
patient
given
suffici
time
opinion
fulli
consid
trial
entri
ask
question
investig
written
inform
consent
form
sign
patient
will
particip
clinic
trial
patient
age
hisher
parent
also
inform
detail
trial
child
hisher
parent
sign
inform
consent
child
may
particip
trial
materi
consent
obtain
specif
address
collect
biolog
sampl
futur
use
serum
plasma
specimen
blind
randomis
system
implement
manag
chines
evidencedbas
termin
experi
cost
provid
research
team
investig
instruct
particip
record
actual
dose
patient
diari
base
diari
investig
evalu
subject
adher
intervent
follow
four
level
record
result
case
report
form
followup
take
prescrib
medic
basic
prescrib
medic
dose
program
data
entri
manag
respons
assign
data
manag
establish
databas
verif
procedur
two
specialis
train
keyboard
oper
input
confirm
data
check
crf
identifi
entri
error
correct
input
data
exactli
crf
queri
crf
commun
research
data
queri
form
data
queri
form
must
process
sign
date
time
research
resolv
data
question
must
return
data
manag
revis
verifi
data
accord
feedback
correspondingli
updat
databas
necessari
data
question
form
queri
databas
lock
confirm
accuraci
establish
databas
blind
review
lock
data
chang
data
revis
need
lock
offici
statement
jointli
sign
sponsor
main
research
experiment
project
manag
statistician
data
manag
must
provid
addit
revis
perform
statist
analysi
primari
outcom
primari
outcom
time
allevi
influenzalik
symptom
fever
stuffi
nose
run
nose
sore
throat
cough
myalgia
fatigu
headach
chill
sweat
measur
hour
allevi
mean
influenzalik
symptom
score
mild
state
stabl
secondari
outcom
secondari
endpoint
consist
seven
aspect
superior
placebo
group
test
group
inferior
posit
control
group
main
index
treatment
effect
period
time
subsid
symptom
hour
report
averag
period
time
remiss
symptom
placebo
group
day
hour
trial
requir
averag
time
symptomat
remiss
test
group
least
hour
shorter
placebo
group
mean
permiss
error
superior
trial
hour
order
consid
clinic
signific
mean
time
symptomat
remiss
posit
group
must
less
hour
compar
placebo
group
mean
permiss
error
superior
trial
within
hour
tabl
base
data
sa
softwar
use
estim
sampl
size
requir
oneway
anova
calcul
result
design
parallel
group
tabl
achiev
adequ
particip
enrol
atient
recruit
clinic
trial
mainli
local
advertis
particip
receiv
financi
compens
finish
entir
treatment
patient
drop
payment
prorat
length
time
stay
studi
payment
made
studi
would
complet
iii
perprotocol
popul
ppp
ppp
case
includ
case
meet
inclus
criteria
full
accord
test
program
violat
protocol
slightli
complet
trial
complet
crf
pp
use
analys
main
indic
evalu
efficaci
examin
consist
result
mitt
iv
safeti
analysi
popul
sap
randomis
studi
drug
taken
least
intervent
effect
safeti
evalu
data
record
least
experi
baselin
data
efficaci
analysi
analys
mittp
simultan
primari
efficaci
endpoint
ppp
analysi
conclus
ii
statist
infer
use
twosid
test
statist
signific
mean
p
confid
interv
paramet
estim
use
confid
interv
iii
efficaci
analys
locf
use
compens
case
inform
patient
record
treatment
last
observ
data
transfer
final
test
result
safeti
analysi
estim
miss
data
minimum
maximum
median
provid
pair
measur
data
also
use
demonstr
differ
mean
standard
deviat
nonparametr
method
median
mean
rank
provid
count
data
frequenc
distribut
correspond
percentag
level
data
given
frequenc
distribut
correspond
percentag
well
median
mean
rank
qualit
inform
show
posit
rate
number
posit
case
denomin
vi
baselin
data
analys
two
set
involv
demograph
indic
gener
situat
primari
secondari
indic
intervent
measur
data
analys
use
test
test
varianc
homogen
count
data
analys
use
pearson
test
rate
data
analys
use
two
sampl
wilcoxon
rank
sum
test
x
safeti
analysi
pearson
test
use
compar
preval
advers
event
two
set
advers
event
occur
trial
list
describ
descript
laboratori
test
result
normalabnorm
chang
experi
well
relationship
abnorm
chang
test
drug
record
chang
also
list
describ
physician
decid
whether
suspend
observ
patient
followup
survey
carri
case
patient
withdrawn
advers
event
result
record
detail
appropri
time
incid
advers
event
treatment
review
comprehens
analys
determin
whether
advers
event
relat
studi
drug
advers
event
lead
discontinu
treatment
seriou
advers
event
summaris
addit
confid
interv
advers
event
use
fisher
exact
test
calcul
fisher
exact
test
use
compar
preval
advers
event
cld
granul
oseltamivir
placebo
studyrel
inform
store
secur
studi
site
particip
inform
store
lock
file
cabinet
area
limit
access
laboratori
specimen
report
data
collect
process
administr
form
identifi
code
id
identif
number
maintain
particip
confidenti
record
contain
name
person
identifi
locat
form
inform
consent
form
store
separ
studi
record
identifi
code
number
local
databas
secur
passwordprotect
access
system
form
list
logbook
appoint
book
list
link
particip
id
trial
publicis
region
nation
confer
final
result
present
scientif
meet
publish
peerreview
journal
authorship
accord
journal
guidelin
addit
lay
summari
studi
result
circul
potenti
interest
parti
direct
patient
involv
design
protocol
sinc
lack
clinic
trial
tradit
chines
herbal
medicin
tchm
effect
also
safeti
tchm
investig
studi
evalu
safeti
chang
liver
kidney
function
treatment
monitor
studi
divid
patient
cold
heat
tcm
syndrom
studi
whether
compet
interest
author
declar
compet
interest
tabl
particip
remov
meet
one
reject
criteria
plausibl
caus
owe
diseas
explan
use
experiment
drug
reason
relationship
time
similar
pharmacolog
effect
drug
experiment
drug
well
known
difficult
identifi
caus
owe
diseas
explan
use
experiment
drug
reason
relationship
time
advers
event
may
caus
diseas
explan
connect
time
test
drug
easi
explain
diseas
main
symptom
diseas
advers
event
definit
caus
reason
test
drug
studi
flowchart
particip
meet
inclus
criteria
recruit
assign
randomli
three
differ
group
particip
accept
treatment
followup
period
observ
data
collect
evalu
treatment
efficaci
safeti
choulingdan
cld
complet
checklist
enter
page
number
manuscript
reader
find
item
list
articl
may
current
address
item
checklist
pleas
modifi
text
includ
miss
inform
certain
item
appli
pleas
write
na
provid
short
explan
upload
complet
checklist
extra
file
submit
journal
method
section
say
use
spirit
report
guidelin
cite
studi
design
multicentr
randomis
doubleblind
doublesimul
oseltamivirand
placebocontrol
paralleldesign
clinic
trial
elig
subject
n
alloc
satisfi
criteria
western
medicin
subject
randomis
receiv
cld
granul
oseltamivir
placebo
day
treatment
type
puls
record
determin
doctor
western
chines
medicin
particip
instruct
compli
protocol
keep
daili
record
symptom
primari
secondari
outcom
safeti
indic
use
evalu
efficaci
clinic
medicin
use
treatment
prevent
influenza
mainli
ion
channel
blocker
exampl
amantadin
rimantadin
neuraminidas
na
inhibitor
exampl
oseltamivir
zanamivir
amantadin
howev
prone
drug
resist
effect
influenza
viru
addit
treatment
effici
amantadin
lower
na
inhibitor
therefor
amantadin
recommend
routin
antibacteri
antiinflammatori
clear
heattox
effect
root
whole
plant
wide
use
treat
cold
sore
throat
bronchiti
malaria
diseas
system
develop
cld
target
drug
less
side
effect
wide
use
prevent
treatment
influenza
indepth
studi
need
conduct
studi
multicentr
randomis
doubleblind
doublesimul
approach
use
hope
clinic
efficaci
cld
treatment
influenza
fulli
verifi
highest
level
clinic
trial
addit
investig
whether
cld
granul
differ
therapeut
effect
differ
tcm
syndrom
differenti
compar
symptom
treatment
prescript
lianhuaqingwen
capsul
treat
influenza
particip
group
receiv
treatment
day
observ
day
followedup
research
interview
day
treatment
studi
flowchart
shown
fig
followup
period
specif
item
collect
see
onlin
supplementari
appendix
remedi
period
particip
requir
regist
daili
record
symptom
symptom
base
western
medicin
case
report
form
crf
tabl
tcm
syndrom
differenti
base
tradit
chines
medicin
tabl
record
pharyngealthroat
swab
upper
respiratori
tract
use
rtpcr
cultiv
influenza
viru
blood
sampl
use
test
influenza
viru
antibodi
inform
beyond
remit
ethic
approv
patient
compli
remov
studi
period
pharyngealthroat
swab
blood
sampl
collect
particip
particip
also
distinguish
accord
tcm
syndrom
differenti
criteria
describ
studi
design
enrol
patient
six
unit
six
unit
includ
main
central
ensur
safeti
patient
blind
studi
design
data
qualiti
adher
studi
protocol
personnel
particip
directli
studi
adequ
train
follow
guidelin
good
clinic
practic
gcp
exclus
criteria
detail
tabl
particip
meet
reject
criteria
remov
data
includ
final
statist
analysi
howev
termin
standard
relat
enrol
patient
may
termin
remedi
period
data
patient
includ
final
statist
analysi
reject
criteria
termin
standard
detail
tabl
tabl
base
detail
symptom
shown
tabl
patient
divid
two
type
accord
two
tcm
practition
inform
consent
doctor
confirm
patient
satisfi
particip
criteria
consent
given
subsequ
discuss
patient
medic
offic
trial
team
patient
materi
consent
obtain
specif
address
collect
biolog
sampl
futur
use
serum
plasma
specimen
blind
randomis
system
implement
manag
chines
evidencedbas
medicin
center
randomis
code
maintain
specif
appoint
independ
custodian
research
particip
inspector
data
entrant
blind
drug
randomli
code
accord
random
protocol
code
number
uniqu
identif
code
particip
accord
order
patient
visit
randomli
divid
differ
group
test
drug
control
drug
placebo
dosag
form
dose
doubleblind
method
use
prepar
drug
requir
uniform
packag
group
use
drug
label
data
lock
perform
crf
data
review
duplic
data
entri
verif
outlier
toler
sever
headach
myalgia
attend
doctor
treat
patient
accord
actual
situat
decid
whether
termin
experi
cost
provid
research
team
investig
instruct
particip
record
actual
dose
patient
diari
base
diari
investig
evalu
subject
adher
intervent
data
entri
manag
respons
assign
data
manag
establish
databas
verif
procedur
two
specialis
train
keyboard
oper
input
confirm
data
check
crf
identifi
entri
error
correct
input
data
exactli
crf
queri
crf
commun
research
data
queri
form
data
queri
form
must
process
sign
date
time
research
resolv
data
question
must
return
data
manag
revis
verifi
data
accord
feedback
correspondingli
updat
databas
necessari
data
question
form
queri
statistician
data
manag
must
provid
addit
revis
perform
statist
analysi
primari
outcom
primari
outcom
time
allevi
influenzalik
symptom
fever
stuffi
nose
run
nose
sore
throat
cough
myalgia
fatigu
headach
chill
sweat
measur
hour
allevi
mean
influenzalik
symptom
score
mild
state
stabl
error
refer
sourc
found
secondari
outcom
secondari
endpoint
consist
seven
aspect
committe
causeandeffect
relationship
advers
event
studi
drug
determin
classif
shown
tabl
patient
seriou
advers
event
necessari
know
specif
situat
medic
unblind
permiss
obtain
consent
main
investig
emerg
letter
read
case
treat
shed
furthermor
trial
confirmatori
studi
treatment
influenza
cld
granul
patient
randomli
assign
three
group
posit
group
test
group
placebo
group
trial
number
sampl
case
estim
base
test
hypothesi
test
group
superior
placebo
group
test
group
inferior
posit
control
group
main
index
treatment
effect
period
time
subsid
symptom
hour
report
averag
period
time
remiss
symptom
consid
clinic
signific
mean
time
symptomat
remiss
posit
group
must
less
hour
compar
placebo
group
mean
permiss
error
superior
trial
within
hour
tabl
base
data
sa
softwar
use
estim
sampl
size
requir
oneway
anova
calcul
result
design
parallel
group
tabl
achiev
adequ
particip
enrol
atient
recruit
clinic
trial
mainli
local
advertis
particip
receiv
financi
compens
finish
entir
treatment
patient
drop
payment
prorat
length
time
stay
studi
payment
made
studi
would
complet
statist
analysi
clinic
data
manag
analys
third
parti
chines
evidencedbas
ii
modifi
intenttotreat
popul
mittp
randomis
studi
drug
use
least
intervent
effect
outcom
record
least
iii
perprotocol
popul
ppp
iv
safeti
analysi
popul
sap
randomis
studi
drug
taken
least
intervent
effect
safeti
evalu
data
record
least
experi
baselin
data
efficaci
analysi
analys
mittp
simultan
primari
efficaci
endpoint
ppp
analysi
conclus
ii
statist
infer
use
twosid
test
statist
signific
mean
p
confid
interv
paramet
estim
use
confid
interv
iii
efficaci
analys
locf
use
compens
case
inform
patient
record
treatment
last
observ
data
transfer
final
test
result
safeti
analysi
estim
miss
data
iv
comparison
dropout
rate
dropout
rate
caus
advers
event
undertaken
use
pearson
test
v
measur
data
given
mean
standard
deviat
confid
interv
necessari
minimum
maximum
median
provid
pair
measur
data
also
use
demonstr
differ
mean
standard
deviat
nonparametr
method
median
mean
rank
provid
count
data
frequenc
distribut
correspond
percentag
level
data
given
frequenc
distribut
correspond
percentag
well
median
mean
rank
qualit
inform
show
posit
rate
number
posit
case
denomin
vi
baselin
data
analys
two
set
involv
demograph
indic
gener
situat
primari
secondari
indic
intervent
measur
data
analys
use
test
test
varianc
homogen
count
data
analys
use
pearson
test
rate
data
analys
use
two
sampl
wilcoxon
rank
sum
test
x
safeti
analysi
pearson
test
use
compar
preval
advers
event
two
set
advers
event
occur
trial
list
describ
descript
laboratori
test
result
normalabnorm
chang
experi
well
relationship
abnorm
chang
test
drug
record
chang
also
list
describ
advers
event
refer
advers
medic
event
occur
time
patient
sign
inform
consent
form
select
trial
time
last
followup
whether
causal
relationship
incid
advers
event
studi
drug
physician
decid
whether
suspend
observ
patient
followup
survey
carri
case
patient
withdrawn
advers
event
result
record
detail
appropri
time
incid
advers
event
treatment
review
comprehens
analys
determin
whether
advers
event
relat
studi
drug
advers
event
lead
discontinu
treatment
seriou
advers
event
summaris
addit
confid
interv
advers
event
use
fisher
exact
test
calcul
fisher
exact
test
use
compar
preval
advers
event
cld
granul
oseltamivir
placebo
inform
consent
obtain
particip
entri
studi
voluntari
particip
ensur
utmost
confidenti
inform
tender
interview
requir
trial
monitor
ethic
committe
treatment
rehabilit
placebo
control
group
provid
basic
drug
trial
clinic
unit
must
compli
gcp
protocol
clinic
trial
pharmaceut
supervisori
administr
depart
occasion
conduct
audit
inspect
cooper
sponsor
send
medic
examin
moder
seriou
advers
event
report
ethic
committe
patient
develop
advers
reaction
trial
receiv
free
medic
treatment
confidenti
studyrel
inform
store
secur
studi
site
particip
inform
store
lock
file
cabinet
area
limit
access
laboratori
specimen
report
data
collect
process
administr
form
identifi
code
id
identif
number
maintain
particip
confidenti
record
contain
name
person
identifi
locat
form
inform
consent
form
store
separ
studi
record
identifi
code
number
local
databas
secur
trial
publicis
region
nation
confer
final
result
present
scientif
meet
publish
peerreview
journal
authorship
accord
journal
guidelin
addit
lay
summari
studi
result
circul
potenti
interest
parti
public
involv
group
includ
mixtur
research
experienc
inexperienc
peopl
tri
work
patient
advocaci
group
ensur
plain
languag
summari
studi
find
share
particip
servic
user
wider
patient
group
commun
particip
research
burden
intervent
assess
comprehens
ration
way
trial
particip
inform
trial
result
directli
howev
final
result
publish
howev
patient
inform
influenza
viru
test
result
followup
visit
direct
patient
involv
design
protocol
sinc
lack
clinic
trial
tradit
chines
herbal
medicin
tchm
effect
also
safeti
tchm
investig
studi
evalu
safeti
chang
liver
kidney
function
treatment
monitor
studi
mainli
base
evidencebas
medicin
indic
use
criteria
quantifi
modern
medicin
syndrom
differenti
tcm
still
controversi
includ
select
criteria
studi
object
observ
data
syndrom
differenti
use
explor
feasibl
quantifi
tcm
symptom
accord
theori
tradit
chines
medicin
cld
may
better
effect
windheat
type
cold
lack
evid
also
hope
find
whether
herbal
medicin
would
comprehens
choulingdan
granul
approv
otc
drug
mani
year
drug
meet
chines
pharmacopoeia
dosag
determin
studi
accord
instruct
manual
howev
clinic
trial
evalu
efficaci
safeti
also
dosag
cld
treatment
influenza
group
howev
consid
limit
narrow
age
rang
summari
limit
clinic
research
su
combin
western
tradit
chines
medicin
evalu
system
evalu
efficaci
safeti
treatment
tchm
influenza
studi
combin
tradit
medicin
evalu
modern
pharmacolog
studi
becom
import
refer
futur
research
promin
featur
studi
use
evidencebas
medicin
better
plausibl
caus
owe
diseas
explan
use
experiment
drug
reason
relationship
time
similar
pharmacolog
effect
drug
experiment
drug
well
known
difficult
identifi
caus
owe
diseas
explan
use
experiment
drug
reason
relationship
time
advers
event
may
caus
diseas
explan
connect
time
test
drug
easi
explain
diseas
main
symptom
diseas
connect
time
test
drug
studi
flowchart
particip
meet
inclus
criteria
recruit
assign
randomli
three
differ
group
particip
accept
treatment
followup
period
observ
data
collect
evalu
treatment
efficaci
safeti
choulingdan
cld
complet
checklist
enter
page
number
manuscript
reader
find
item
list
articl
may
current
address
item
checklist
pleas
modifi
text
includ
miss
inform
certain
item
appli
pleas
write
na
provid
short
explan
upload
complet
checklist
extra
file
submit
journal
method
section
say
use
spirit
report
guidelin
cite
chan
